The neuropsychological performance of 85 women with early stage breast cancer scheduled for chemotherapy, 43 women scheduled for endocrine therapy and/or radiotherapy and 49 healthy control subjects was assessed at baseline (T1), postchemotherapy (or 6 months) (T2) and at 18 months (T3). Repeated measures analysis found no significant interactions or main effect of group after controlling for age and intelligence. Using a calculation to examine performance at an individual level, reliable decline on multiple tasks was seen in 20% of chemotherapy patients, 26% of nonchemotherapy patients and 18% of controls at T2 (18%, 14 and 11%, respectively, at T3). Patients who had experienced a treatment-induced menopause were more likely to show reliable decline on multiple measures at T2 (OR ¼ 2.6, 95% confidence interval (CI) 0.823 -8.266 P ¼ 0.086). Psychological distress, quality of life measures and self-reported cognitive failures did not impact on objective tests of cognitive function, but were significantly associated with each other. The results show that a few women experienced objective measurable change in their concentration and memory following standard adjuvant therapy, but the majority were either unaffected or even improve over time.
Summary.-The serum concentrations of the radiosensitizer metronidazole have been determined in mice for both oral and intraperitoneal doses of the drug and these have been related to radiosensitization studies in murine tumour systems.In preliminary work before a possible clinical trial the serum metronidazole concentration/time curves have been determined in 7 patients using single doses of metronidazole of up to 15 g. The data suggest that a linear relationship exists between the metronidazole dose expressed in mg/kg and the peak serum concentration.The possibility of achieving radiosensitization of tumours in patients after tolerable doses of metronidazole is discussed in relation to enhancement ratios determined for in vitro and in vivto systems. It is concluded that predictions from in vitro systems give values that are probably too optimistic.
This prospective study investigated whether low-dose ionising radiotherapy preserved vision and caused membrane regression in patients with age-related subfoveal neovascular membranes (SFNVMs) or vascularised pigment epithelial detachments (PEDs) and relatively good initial visual acuities. Twenty-five patients with initial Snellen acuities of 6/24 or better were treated with low-dose external beam radiotherapy. Of the patients with SFNVMs, visual acuities were maintained or improved in 58% at 6 months and 53% at 1 year. Neovascular membrane size was assessed by image analysis and showed some regression in 47% and 41% at 6 and 12 months respectively. These results suggest that patients with SFNVMs and good vision may benefit from radiotherapy, faring better than previous reports of the natural history of this condition. Conversely, patients with vascularised PEDs did not appear to benefit from radiotherapy. Only 17% maintained their vision at 1 year and 33% suffered retinal pigment epithelial tears. The results from patients with SFNVMs and good initial vision, excluding those with vascularised PEDs, are encouraging however, any benefit from this treatment needs to be proven by controlled trials with long follow-up.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.